Po-Heng Tsai, MD
Behavioral Neurology & Neuropsychiatry · Phoenix, AZNPI 1952532475
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 8 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Roche Diagnostics Corporation at 31.2% of the total.
Across 8 payments — averaging $91.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Roche Diagnostics Corporation$228
- Novo Nordisk$209
- Eisai Inc.$146
- Biogen$134
- Boston Scientific$14
Across 40 payments — averaging $43,068 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$813K
- Eisai Inc.$487K
- Eli Lilly$423K
What the payments were for
- Food & beverage$731100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Roche Diagnostics Corporation | 2 | $228 |
| Novo Nordisk | 2 | $209 |
| Eisai Inc. | 2 | $146 |
| Biogen | 1 | $134 |
| Boston Scientific | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few behavioral neurology & neuropsychiatry providers in Arizonato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rivastigmine | 63 | $13,700 |
| Memantine Hcl | 176 | $8,317 |
| Galantamine ErGalantamine Hbr | 66 | $5,554 |
| Donepezil Hcl | 309 | $4,384 |
| Escitalopram Oxalate | 132 | $1,495 |
| Sertraline Hcl | 75 | $1,189 |
| Mirtazapine | 36 | $930 |
| RivastigmineRivastigmine Tartrate | 12 | $593 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 13 | $484 |
| Duloxetine Hcl | 24 | $463 |
| Trazodone Hcl | 46 | $364 |
Paid to pharmacies, not to this prescriber.
Other behavioral neurology & neuropsychiatry in Phoenix
- Claire AdamsPhoenix$133
- Sandra CombsTucson$752
- Frederique DelhayeSierra Vista$125
- Gigi FoxWickenburg$29
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.